- Home
- FULC vs KMDA Comparison
FULC vs KMDA Comparison
Compare FULC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- KMDA
- Stock Information
- Founded
- FULC 2015
- KMDA 1990
- Country
- FULC United States
- KMDA Israel
- Employees
- FULC N/A
- KMDA N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- KMDA Health Care
- Exchange
- FULC Nasdaq
- KMDA Nasdaq
- Market Cap
- FULC 372.2M
- KMDA 410.6M
- IPO Year
- FULC 2019
- KMDA N/A
- Fundamental
- Price
- FULC $7.44
- KMDA $6.98
- Analyst Decision
- FULC Buy
- KMDA Strong Buy
- Analyst Count
- FULC 8
- KMDA 2
- Target Price
- FULC $7.13
- KMDA $13.00
- AVG Volume (30 Days)
- FULC 398.4K
- KMDA 50.0K
- Earning Date
- FULC 11-12-2025
- KMDA 11-12-2025
- Dividend Yield
- FULC N/A
- KMDA 2.90%
- EPS Growth
- FULC N/A
- KMDA 27.97
- EPS
- FULC N/A
- KMDA 0.32
- Revenue
- FULC N/A
- KMDA $169,517,000.00
- Revenue This Year
- FULC N/A
- KMDA $14.49
- Revenue Next Year
- FULC N/A
- KMDA $10.12
- P/E Ratio
- FULC N/A
- KMDA $20.92
- Revenue Growth
- FULC 2752.05
- KMDA 9.67
- 52 Week Low
- FULC $2.32
- KMDA $5.17
- 52 Week High
- FULC $8.50
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- FULC 59.83
- KMDA 45.69
- Support Level
- FULC $6.69
- KMDA $6.84
- Resistance Level
- FULC $7.50
- KMDA $7.15
- Average True Range (ATR)
- FULC 0.40
- KMDA 0.19
- MACD
- FULC 0.07
- KMDA -0.00
- Stochastic Oscillator
- FULC 71.38
- KMDA 28.57
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.